Stock Analysis of Immuneering Corp (IMRX) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code IMRX
Close 1.47
Change -0.070 / 4.55 %
Volume 184023
Vol Change 60845.00 / 49.40 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthStrong Bearish
Growth Index No Significant Growth
Value Index No Significant Value
Profitability Index Poor Profitability Stock
Stability Index Mild Stability


Fundamental View of Immuneering Corp
PE (TTM)

-0.281

Very Poor
Price / Book

0.181

Excellent
Price / Sales

0

Very Poor
Piotroski F Score

3.0

Not Good
Market Cap

43590.50 K

Enterprise Value

-59062.12 M

ROA (TTM)

-58.79

Very Poor
ROE (TTM)

-64.50

Very Poor
Net Margin (TTM)

0

Poor
Revenue

99.86 %

455.00
Net Profit

2.22 %

-51633.69 K
Debt to Equity

0.0033

Excellent
Altman Z Score

-2.23

Very Poor
Quick Ratio

0

Poor
Cash Ratio

10.92

Excellent


Highs/Lows of Immuneering Corp
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week1.45 1.38 % 1.54 % 1.63941.4515-May-2413-May-24
Two Week1.64 10.37 % 3.42 % 1.77831.406-May-2410-May-24
One Month1.86 20.97 % 5.60 % 1.891.3818-Apr-2401-May-24
Three Month6.6 77.73 % 5.95 % 7.681.3804-Mar-2401-May-24
Six Months5.6 73.75 % 17.48 % 8.891.3804-Dec-2301-May-24
One year8.66 83.03 % 27.52 % 11.921.3821-Jun-2301-May-24
Two year5.06 70.95 % 29.70 % 16.1671.3830-Sep-2201-May-24


Technical View of Immuneering Corp
RSI

34.32

Neutral
MACD

-0.234

Strong Bullish
ADX

41.25

Mild Bearish
Super Trend

1.98

Mild Bearish
Williams %R

-77.40

Neutral
CCI

-64.93

Neutral


EMA 5

1.53

Strong Bearish
EMA 15

1.59

Strong Bearish
EMA 50

2.51

Mild Bearish
EMA 100

3.80

Mild Bearish
SMA 100

4.35

Mild Bearish
SMA 200

5.95

Strong Bearish
SMA 5 / 20

1.55 / 1.55

Bullish
SMA 15 / 50

1.55 / 2.31

Mild Bearish
SMA 50 / 200

2.31 / 5.95

Strong Bearish




Charts of Immuneering Corp


Returns of Immuneering Corp with Peers
Period / StockIMRXBGXXOCUPIRIX
1 Week1.38%8.54%-2.03%-6.34%
1 Mth-20.97%5.50%-3.16%-16.35%
3 Mth-77.73%2.68%-35.93%1.14%
6mth-73.75%-24.09%-42.49%34.34%
1 Year-83.03%-76.53%-64.53%16.16%
2 Year-70.95%--23.76%-13.92%
5 Years---91.69%-46.48%
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Immuneering Corp with Peers
Ratio / StockIMRXBGXXOCUPIRIX
PE-0.281-2.60-837.78-3.94
P/B0.1815.47210.213.75
ROA-58.79-97.27-22.71-30.17
ROE-64.50-128.48-25.09-95.32
Debt To Equity0.00330.16900.104
Revenue455.00
99.86 % 		401491
97.24 % 		57208.00 K
43.56 % 		51869.00 K
8.96 %
Net Income-51633.69 K
2.22 % 		-9574.30 K
65.39 % 		28750.00 K
60.72 % 		-9570.00 K
26.81 %


Technicals of Immuneering Corp with Peers
Technical / StockIMRXBGXXOCUPIRIX-
ADX41.2521.6122.4919.36
CMF-0.1230.054-0.249-0.157
MFI60.6270.1959.9655.10
RSI34.3253.5244.2541.00
MACD Abv SignalTrueTrueTrueFalse
Price Above 50 MAFalseFalseFalseFalse-
Price Above 200 MAFalseFalseFalseTrue-


About : Immuneering Corp

Address : 245 Main Street, Cambridge, MA, United States, 02142
Tel : 617 500 8080
URL : https://immuneering.com
Code : IMRX, ISIN : US45254E1073, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 30_Jul_2021
Employee Count : 65

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.


Note : All Data Generated at the End of Trading Hours (EOD Data)